174671-46-6 | 5-Fluorobenzo[c][1,2]oxaborol-1(3h)-ol

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$25.00	$18.00
1g	98%	in stock	$36.00	$25.00
5g	98%	in stock	$175.00	$122.00
10g	98%	in stock	$333.00	$233.00
25g	98%	in stock	$713.00	$499.00

Description

• Catalog Number: AA92956
• Chemical Name: 5-Fluorobenzo[c][1,2]oxaborol-1(3h)-ol
• CAS Number: 174671-46-6
• Molecular Formula: C7H6BFO2
• Molecular Weight: 151.9307
• MDL Number: MFCD10699483
• SMILES: Fc1ccc2c(c1)COB2O

Computed Properties

• Complexity: 155
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1

Literature

• Tavaborole: first global approval.

  Drugs 20140901

• The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.

  Journal of drugs in dermatology : JDD 20140901

• Characterization of benzoxaborole-based antifungal resistance mutations demonstrates that editing depends on electrostatic stabilization of the leucyl-tRNA synthetase editing cap.

  FEBS letters 20111003

• Boron-containing inhibitors of synthetases.

  Chemical Society reviews 20110801

• 5-Fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol.

  Acta crystallographica. Section E, Structure reports online 20110201

• Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690.

  The Biochemical journal 20100901

• Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.

  Journal of molecular biology 20090710

• A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite Plasmodium falciparum.

  BMC genomics 20090101

• In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.

  Journal of pharmaceutical sciences 20071001

• AN-2690, a novel antifungal for the topical treatment of onychomycosis.

  Current opinion in investigational drugs (London, England : 2000) 20070801

• An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.

  Science (New York, N.Y.) 20070622

• Recent progress on the topical therapy of onychomycosis.

  Expert opinion on investigational drugs 20070201

• Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.

  Journal of medicinal chemistry 20060727

• Spotlight on targeting aminoacyl-tRNA synthetases for the treatment of fungal infections.

  Drug news & perspectives 20060101